Annals of Surgical Treatment and Research

The Korean Surgical Society (대한외과학회)
권호 표지

Comparison of Tamoxifen and Toremifene as Adjuvant Treatment in Node-negative Postmenopausal Breast Cancer

림프절전이가 없는 폐경 후 유방암의 호르몬치료제로서 Tamoxifen과 Toremifene의 비교

Han, Se-Hwan;Yang, Keun-Ho;Bae, Byung-Noe;Kim, Ki-Hwan;Kim, Hong-Joo;Kim, Young-Duck;Kim, Hong-Yong
한세환;양근호;배병노;김기환;김홍주;김영덕;김홍용

  • Published : 20021000
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the differences in therapeutic efficacy and toxicity profiles between adjuvant toremifene and tamoxifene in postmenopausal breast cancer patients. Methods: Toremifene 40 mg (n=115) and tamoxifen 20 mg (n =116) were administered daily for more than 2 years after curative surgery for lymph node-negative breast cancer. Toxicity profiles were compared between the two groups and the patient survival rate was also analyzed. Results: Sweating and hot flashes were the most common symptoms in the two groups (toremifene vs. tamoxifen=47.8% vs. 49.1%). Increase of vaginal discharge (39.1% vs. 36.2%) and weight gain (21.7% vs. 24.1%) were the next following adverse effects. There was no significant difference in adverse effect between the two groups. During the median follow-up period of 25 months (range: 9$\sim$38 months), five (4.3%) and four (3.3%) patients treated by toremifene and tamoxifen, respectively, had recurrent disease. Conclusion: The clinical outcome and adverse effect profiles of toremifene were similar to those of tamoxifen. Toremifene at 40 mg/day seems to be as safe and effective as tamoxifen at 20 mg/day in the treatment of postmenopausal, node-negative, breast cancer. However, a longer follow-up study is needed to verify this.

Keywords

References

  1. Jaiyesimi lA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 1995;13:513-29. https://doi.org/10.1200/JCO.1995.13.2.513
  2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;351:1451-67. https://doi.org/10.1016/S0140-6736(97)11423-4
  3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-8. https://doi.org/10.1093/jnci/90.18.1371
  4. Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, et al. Comparison of toremifene and tamoxifen in postmenopausal patient with advanced breast cancer: A randomized double-blind The Nordic phase III study. Br J Cancer 1997;76:270-7. https://doi.org/10.1038/bjc.1997.375
  5. Homesley HD, Shemano I, Gams R, Harry DS, Hickox PG, Rebar RW, et al. Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. Am J Clin Oncol 1993;16:117-22. https://doi.org/10.1097/00000421-199304000-00007
  6. Di Salle E, Zaccheo T, Ornati G. Antiestrogenic and antiturmr properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 1990;36:203-6. https://doi.org/10.1016/0022-4731(90)90005-D
  7. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;351:1451-67. https://doi.org/10.1016/S0140-6736(97)11423-4
  8. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast career. J Natl Cancer lust 1996;88:1543-9. https://doi.org/10.1093/jnci/88.21.1543
  9. Love RR. Prospects for antiestrogen chemoprevention of brest cancer. J Natl Cancer Inst 1990;82:18-22. https://doi.org/10.1093/jnci/82.1.18
  10. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6. https://doi.org/10.1056/NEJM199203263261302
  11. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991;115:860-4. https://doi.org/10.7326/0003-4819-115-11-860
  12. Turken S, Siris E, Seldin D, Flaster E, Heyman G, Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989;1086-88.
  13. Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flandir M, et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positiie breast cancer. J Clin Oncol 2000;18:3487-94. https://doi.org/10.1200/JCO.2000.18.20.3487
  14. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DC, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37. https://doi.org/10.1093/jnci/86.7.527
  15. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52. https://doi.org/10.1016/S0140-6736(94)92692-1
  16. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early-stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87:645-51. https://doi.org/10.1093/jnci/87.9.645
  17. Ellmen J, Werner D, Hakulinen P, Keiling R, Forgeot P, Falkeson G, et al. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients. Cancer Chemother Pharmacol 2000;402-8. https://doi.org/10.1007/s002800051009